The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...

Continued drug shortages remain a possibility, and recent moves by the government could create or exacerbate cancer drug ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

US FDA grants orphan drug designation to Zenith Epigenetics’ ZEN-3694 to treat NUT carcinoma: Calgary, Alberta Tuesday, October 28, 2025, 17:00 Hrs [IST] Zenith Epigenetics Ltd.

Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...

Female sex at birth, age of 65 years or older, and 32 specific medications were identified as factors for drug-related candidiasis.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Prior research on the potential role of cytokines found that IL-6 signaling can reprogram and alter T-cell immune responses ...

FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.